Chief Medical Officer Zach Roberts said the company expects to report initial data in April from its ALPHA3 study, a ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 12:15 PM ESTCompany ParticipantsZachary Roberts ...

Quest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic ...

NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026 NeoGenomics, Inc. misses on earnings ...

Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the ...

Q4 2025 Earnings Call February 17, 2026 8:30 AM ESTCompany ParticipantsKendra Sweeney - Vice President of Investor Relations ...

Mizuho believes Tempus AI is being underestimated. The bank initiated the AI-powered health technology firm with an outperform rating and $100 price target, implying an upside of 78% from Wednesday's ...

In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...

Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results , with sales up 10.6% year on year to $190.2 million. The company expects the full year’s revenue to be around ...

GRAIL reported that 2025 total revenue rose 17% year on year to $147.2 million, driven by a 26% increase in U.S. Galleri sales to $136.8 million, while net loss narrowed sharply to $408.4 million and ...